Qui M - Search Results

1

Early T cell and binding antibody responses are associated with COVID-19 RNA vaccine efficacy onset.

Kalimuddin S, Tham CYL, Qui M, de Alwis R, Sim JXY, Lim JME, Tan HC, Syenina A, Zhang SL, Le Bert N, Tan AT, Leong YS, Yee JX, Ong EZ, Ooi EE, Bertoletti A, Low JG. Kalimuddin S, et al. Among authors: qui m. Med. 2021 Jun 11;2(6):682-688.e4. doi: 10.1016/j.medj.2021.04.003. Epub 2021 Apr 8. Med. 2021. PMID: 33851143 Free PMC article.

2

Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals.

Tan AT, Lim JM, Le Bert N, Kunasegaran K, Chia A, Qui MD, Tan N, Chia WN, de Alwis R, Ying D, Sim JX, Ooi EE, Wang LF, Chen MI, Young BE, Hsu LY, Low JG, Lye DC, Bertoletti A. Tan AT, et al. J Clin Invest. 2021 Sep 1;131(17):e152379. doi: 10.1172/JCI152379. J Clin Invest. 2021. PMID: 34623327 Free PMC article.

3

SARS-CoV-2-specific T cells in infection and vaccination.

Bertoletti A, Le Bert N, Qui M, Tan AT. Bertoletti A, et al. Among authors: qui m. Cell Mol Immunol. 2021 Oct;18(10):2307-2312. doi: 10.1038/s41423-021-00743-3. Epub 2021 Sep 1. Cell Mol Immunol. 2021. PMID: 34471260 Free PMC article. Review.

4

Favorable vaccine-induced SARS-CoV-2-specific T cell response profile in patients undergoing immune-modifying therapies.

Qui M, Le Bert N, Chan WPW, Tan M, Hang SK, Hariharaputran S, Sim JXY, Low JGH, Ng W, Wan WY, Ang TL, Bertoletti A, Salazar E. Qui M, et al. J Clin Invest. 2022 Jun 15;132(12):e159500. doi: 10.1172/JCI159500. J Clin Invest. 2022. PMID: 35536644 Free PMC article.

5

A Virus-Specific Immune Rheostat in the Immunome of Patients Recovering From Mild COVID-19.

Yeo JG, Leong JY, Tay SH, Nadua KD, Anderson DE, Lim AJM, Ng XW, Poh SL, Guo D, Yaung KN, Kumar P, Wasser M, Hazirah SN, Sutamam N, Chua CJH, Qui M, Foo R, Gamage AM, Yeo KT, Ramakrishna L, Arkachaisri T, Young BE, Lye DC, Wang LF, Chong CY, Tan NWH, Li J, Kam KQ, Ginhoux F, Thoon KC, Chan JKY, Yung CF, Albani S. Yeo JG, et al. Among authors: qui m. Front Immunol. 2021 May 25;12:674279. doi: 10.3389/fimmu.2021.674279. eCollection 2021. Front Immunol. 2021. PMID: 34113347 Free PMC article.

6

A multiplexed time-resolved fluorescence resonance energy transfer ultrahigh-throughput screening assay for targeting the SMAD4-SMAD3-DNA complex.

Ouyang W, Li Q, Niu Q, Qui M, Fu H, Du Y, Mo X. Ouyang W, et al. Among authors: qui m. J Mol Cell Biol. 2024 Apr 10;15(11):mjad068. doi: 10.1093/jmcb/mjad068. J Mol Cell Biol. 2024. PMID: 37968137

7

Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.

Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Clinical Trial.

8

A Novel 7H-[1,2,4]Triazolo[3,4-b]thiadiazine-based Cystic Fibrosis Transmembrane Conductance Regulator Potentiator Directed toward Treatment of Cystic Fibrosis.

Rab A, Yang X, Tracy WF, Hong JS, Joshi D, Manfredi C, Ponnaluri SS, Kolykhalov AA, Qui M, Fu H, Du Y, Davies HML, Sorscher EJ. Rab A, et al. Among authors: qui m. ACS Med Chem Lett. 2023 Sep 20;14(10):1338-1343. doi: 10.1021/acsmedchemlett.3c00155. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849531 Free PMC article.

9

Constitutively Synergistic Multiagent Drug Formulations Targeting MERTK, FLT3, and BCL-2 for Treatment of AML.

Kelvin JM, Jain J, Thapa A, Qui M, Birnbaum LA, Moore SG, Zecca H, Summers RJ, Switchenko JM, Costanza E, Uricoli B, Wang X, Jui NT, Fu H, Du Y, DeRyckere D, Graham DK, Dreaden EC. Kelvin JM, et al. Among authors: qui m. Pharm Res. 2023 Sep;40(9):2133-2146. doi: 10.1007/s11095-023-03596-9. Epub 2023 Sep 13. Pharm Res. 2023. PMID: 37704893

10

Development of constitutively synergistic nanoformulations to enhance chemosensitivity in T-cell leukemia.

Kelvin JM, Chimenti ML, Zhang DY, Williams EK, Moore SG, Humber GM, Baxter TA, Birnbaum LA, Qui M, Zecca H, Thapa A, Jain J, Jui NT, Wang X, Fu H, Du Y, Kemp ML, Lam WA, Graham DK, DeRyckere D, Dreaden EC. Kelvin JM, et al. Among authors: qui m. J Control Release. 2023 Sep;361:470-482. doi: 10.1016/j.jconrel.2023.07.045. Epub 2023 Aug 14. J Control Release. 2023. PMID: 37543290

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page